APO RESEARCH · REPORT
Covid-19 Vaccine
A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
Product & engineering
Understand the product.
A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.
The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.
Selected research
Industry Research
Covid-19 Vaccine Industry Research Report 2026
Market perspective
A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.
The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.
Read the full market overview
North America is the largest consumption place, with a consumption market share nearly 53.8% in 2026, Europe is the second largest consumption place with the consumption market share of 24.61% in 2026.
Report Scope
This report quantifies the global Covid-19 Vaccine market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Covid-19 Vaccine.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Covid-19 Vaccine Market by Company
Moderna
CanSino Biologicals
Inovio Pharmaceuticals
Shenzhen Geno-Immune Medical Institute
GlaxoSmithKine
Pfizer
Johnson＆Johnson
Heat Biologics
Sanofi
Covid-19 Vaccine Segment by Type
DNA
Non-replicating Viral Vector
Protein Subunit
RNA
Others
Covid-19 Vaccine Segment by Application
Adults
Children
Covid-19 Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Covid-19 Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Covid-19 Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Covid-19 Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Covid-19 Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- DNA
- Non-replicating Viral Vector
- Protein Subunit
- RNA
- Others
Applications
- Adults
- Children
Companies covered
- Moderna
- CanSino Biologicals
- Inovio Pharmaceuticals
- Shenzhen Geno-Immune Medical Institute
- GlaxoSmithKine
- Pfizer
- Johnson＆Johnson
- Heat Biologics
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Covid-19 Vaccine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 DNA
- 2.2.3 Non-replicating Viral Vector
- 2.2.4 Protein Subunit
- 2.2.5 RNA
- 2.2.6 Others
- 2.3 Covid-19 Vaccine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Adults
- 2.3.3 Children
- 2.4 Assumptions and Limitations
3 Covid-19 Vaccine Breakdown Data by Type
- 3.1 Global Covid-19 Vaccine Historic Market Size by Type (2021-2026)
- 3.2 Global Covid-19 Vaccine Forecasted Market Size by Type (2027-2032)
4 Covid-19 Vaccine Breakdown Data by Application
- 4.1 Global Covid-19 Vaccine Historic Market Size by Application (2021-2026)
- 4.2 Global Covid-19 Vaccine Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Covid-19 Vaccine Market Perspective (2021-2032)
- 5.2 Global Covid-19 Vaccine Growth Trends by Region
- 5.2.1 Global Covid-19 Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Covid-19 Vaccine Historic Market Size by Region (2021-2026)
- 5.2.3 Covid-19 Vaccine Forecasted Market Size by Region (2027-2032)
- 5.3 Covid-19 Vaccine Market Dynamics
- 5.3.1 Covid-19 Vaccine Industry Trends
- 5.3.2 Covid-19 Vaccine Market Drivers
- 5.3.3 Covid-19 Vaccine Market Challenges
- 5.3.4 Covid-19 Vaccine Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Covid-19 Vaccine Players by Revenue
- 6.1.1 Global Top Covid-19 Vaccine Players by Revenue (2021-2026)
- 6.1.2 Global Covid-19 Vaccine Revenue Market Share by Players (2021-2026)
- 6.2 Global Covid-19 Vaccine Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Covid-19 Vaccine Head Office and Area Served
- 6.4 Global Covid-19 Vaccine Players, Product Type & Application
- 6.5 Global Covid-19 Vaccine Manufacturers Established Date
- 6.6 Global Covid-19 Vaccine Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Covid-19 Vaccine Market Size (2021-2032)
- 7.2 North America Covid-19 Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Covid-19 Vaccine Market Size by Country (2021-2026)
- 7.4 North America Covid-19 Vaccine Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Covid-19 Vaccine Market Size (2021-2032)
- 8.2 Europe Covid-19 Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Covid-19 Vaccine Market Size by Country (2021-2026)
- 8.4 Europe Covid-19 Vaccine Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Covid-19 Vaccine Market Size (2021-2032)
- 9.2 Asia-Pacific Covid-19 Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Covid-19 Vaccine Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Covid-19 Vaccine Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Covid-19 Vaccine Market Size (2021-2032)
- 10.2 South America Covid-19 Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Covid-19 Vaccine Market Size by Country (2021-2026)
- 10.4 South America Covid-19 Vaccine Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Covid-19 Vaccine Market Size (2021-2032)
- 11.2 Middle East & Africa Covid-19 Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Covid-19 Vaccine Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Covid-19 Vaccine Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Moderna
- 12.1.1 Moderna Company Information
- 12.1.2 Moderna Business Overview
- 12.1.3 Moderna Revenue in Covid-19 Vaccine Business (2021-2026)
- 12.1.4 Moderna Covid-19 Vaccine Product Portfolio
- 12.1.5 Moderna Recent Developments
- 12.2 CanSino Biologicals
- 12.2.1 CanSino Biologicals Company Information
- 12.2.2 CanSino Biologicals Business Overview
- 12.2.3 CanSino Biologicals Revenue in Covid-19 Vaccine Business (2021-2026)
- 12.2.4 CanSino Biologicals Covid-19 Vaccine Product Portfolio
- 12.2.5 CanSino Biologicals Recent Developments
- 12.3 Inovio Pharmaceuticals
- 12.3.1 Inovio Pharmaceuticals Company Information
- 12.3.2 Inovio Pharmaceuticals Business Overview
- 12.3.3 Inovio Pharmaceuticals Revenue in Covid-19 Vaccine Business (2021-2026)
- 12.3.4 Inovio Pharmaceuticals Covid-19 Vaccine Product Portfolio
- 12.3.5 Inovio Pharmaceuticals Recent Developments
- 12.4 Shenzhen Geno-Immune Medical Institute
- 12.4.1 Shenzhen Geno-Immune Medical Institute Company Information
- 12.4.2 Shenzhen Geno-Immune Medical Institute Business Overview
- 12.4.3 Shenzhen Geno-Immune Medical Institute Revenue in Covid-19 Vaccine Business (2021-2026)
- 12.4.4 Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Product Portfolio
- 12.4.5 Shenzhen Geno-Immune Medical Institute Recent Developments
- 12.5 GlaxoSmithKine
- 12.5.1 GlaxoSmithKine Company Information
- 12.5.2 GlaxoSmithKine Business Overview
- 12.5.3 GlaxoSmithKine Revenue in Covid-19 Vaccine Business (2021-2026)
- 12.5.4 GlaxoSmithKine Covid-19 Vaccine Product Portfolio
- 12.5.5 GlaxoSmithKine Recent Developments
- 12.6 Pfizer
- 12.6.1 Pfizer Company Information
- 12.6.2 Pfizer Business Overview
- 12.6.3 Pfizer Revenue in Covid-19 Vaccine Business (2021-2026)
- 12.6.4 Pfizer Covid-19 Vaccine Product Portfolio
- 12.6.5 Pfizer Recent Developments
- 12.7 Johnson＆Johnson
- 12.7.1 Johnson＆Johnson Company Information
- 12.7.2 Johnson＆Johnson Business Overview
- 12.7.3 Johnson＆Johnson Revenue in Covid-19 Vaccine Business (2021-2026)
- 12.7.4 Johnson＆Johnson Covid-19 Vaccine Product Portfolio
- 12.7.5 Johnson＆Johnson Recent Developments
- 12.8 Heat Biologics
- 12.8.1 Heat Biologics Company Information
- 12.8.2 Heat Biologics Business Overview
- 12.8.3 Heat Biologics Revenue in Covid-19 Vaccine Business (2021-2026)
- 12.8.4 Heat Biologics Covid-19 Vaccine Product Portfolio
- 12.8.5 Heat Biologics Recent Developments
- 12.9 Sanofi
- 12.9.1 Sanofi Company Information
- 12.9.2 Sanofi Business Overview
- 12.9.3 Sanofi Revenue in Covid-19 Vaccine Business (2021-2026)
- 12.9.4 Sanofi Covid-19 Vaccine Product Portfolio
- 12.9.5 Sanofi Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst